All Posts Tagged With: "GILD"
(GILD) Gilead Sciences Shows Uptrend in Earnings Estimates
Earnings estimates for Gilead Sciences (GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90 cents, well...
(GILD) Gilead Sciences Earns FDA Approval for Cayston Drug
In a positive development, Gilead Sciences (GILD) received long-awaited US Food and Drug Administration (FDA) approval for Cayston (aztreonam for inhalation solution). The drug is indicated for the treatment...
(GILD) Gilead Sciences – Earnings Report Posts Record-Setting Quarter
Gilead Sciences, Inc (GILD) posted record sales last week and analysts continue to raise estimates. The double-digit growth rates are also coming at a great value.
Company Description
Gilead...
(GILD) Gilead Sciences – Bull of the Day
Gilead Sciences (GILD) reported another strong quarter with earnings per share coming in at $0.90, well above the Zacks Consensus Estimate of $0.82 and the year-ago quarter’s earnings of $0.59. For...
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(GILD) Gilead Sciences’ Reports Results 42% Ahead of Last Year
Gilead Sciences (GILD) has reported a strong fourth quarter and full year results. The company reported quarterly revenues of $2.03 billion, up 42% compared to the year-ago period. Gilead’s earnings per...
(MRK) Merck Sees Setback With One of its Pipeline Drugs
Merck (MRK) received a setback recently with respect to one of its pipeline candidates, vicriviroc. The drug did not meet the primary efficacy endpoint in two late stage studies (phase III) with HIV patients...
($JPM) JP Morgan Healthcare Conference in San Francisco
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 13, 2010: Issue...
(GILD) Gilead Sciences Suffers Stage III Setback
Gilead Sciences (GILD) received a major pipeline setback with disappointing results from a phase III trial of darusentan in which it failed to achieve its primary endpoint. The drug was being studied under...
(GILD) Gilead Sciences Closer to FDA Approval
Gilead Sciences, Inc (GILD) received a positive opinion from the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA). Gilead is seeking FDA approval for inhalable aztreonam...
(GILD) Gilead Sciences-GlaxoSmithKline Deal Targets Asia
Recently, Gilead Sciences (GILD) entered into a licensing agreement with GlaxoSmithKline (GSK) to commercialize Viread (tenofovir disoproxil...
(GILD) Gilead Sciences Awaits Committee Outcome
Gilead Sciences, Inc (GILD) is awaiting the outcome of the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) scheduled on December 10, 2009. The committee will review Gilead...
(GILD) Top Franklin Templeton Funds – Mutual Fund Education
Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms.
This non-diversified fund may invest a substantial portion of assets in equity securities...
(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance...
(UTHR) United Therapeutics Corporation Misses Earnings Estimates
United Therapeutics Corporation (UTHR) reported a net income of 21 cents per share in the third quarter, well below the Zacks Consensus Estimate of 31 cents. The company reported earnings of 22 cents in the...
(GILD) Gilead Sciences Presented Positive Data From Two Phase III Clinical Trials
Gilead Sciences Inc. (GILD) recently presented positive data from a 3 year (144-week) open label two pivotal phase III clinical trials – Studies 102 and 103, evaluating the safety and efficacy of once-daily...
(GILD) Gilead Sciences’ Strong Performance
Gilead Sciences (GILD) posted strong third quarter results yesterday. The company’s earnings per share of 74 cents was well above the Zacks Consensus Estimate of 69 cents and last year’s profit of 52 cents. Gilead reported $1.8 billion of revenues during...
(JNJ) Johnson & Johnson Beast Estimates and Raises Guidance
Johnson & Johnson’s (JNJ) third quarter earnings of $1.20 surpassed the Zacks Consensus Estimate by 7 cents and by 3 cents from the year-ago period.
However, the company reported revenues of $15.1 billion, a decline of 5.3% compared to the third...
(GILD) Top Franklin Templeton Funds – Mutual Fund Education
Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms.
This non-diversified fund may invest a substantial portion of assets in...
(MRK) Merck’s Isentress Wins Approval from the Food and Drug Administration
The European Union (EU) recently expanded the approval of Merck’s (MRK) Isentress (raltegravir) for the first line treatment of HIV patients. Earlier, it was approved for patients who had not responded to other treatment options. In the US, following a recent...
(MYL) Mylan’s Portfolio Strengthens
We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed...
(MYL) Mylan Drug Gets Tentative OK
Yesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from the US Food and Drug Administration (FDA) under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its generic version of...
(WYE) Biotech Industry – Industry Outlook
OVERVIEW
The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009.
Large biotech companies are doing OK since they...
(GILD) Gilead Sciences Inc. – Momentum – Zacks Rank Buy
Gilead Sciences Inc. (GILD) continues to grow its earnings in a tough market on the strength of its HIV drug franchise. Gilead’s fourth-quarter results, reported on Jan 29, were once again of expectations.
Revenue was up 30% from...
(GILD) Gilead Sciences – estimates have continued to tick higher over the last few months
Gilead Sciences, Inc.’s (GILD) share price continues to head north in response to higher estimates related to the strength of the company’s HIV drug franchise.
Company Description
Gilead Sciences, Inc. is a biopharmaceutical company that develops...